Adverse Drug Reactions Affecting Blood Cells

  • Richard H. AsterEmail author
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 196)


Numerous medications and other xenobiotics are capable of producing adverse reactions (ADRs) affecting red cells, platelets or neutrophils. Occasionally, more than one blood element is affected simultaneously. As with all drug reactions, some side effects are a direct consequence of a known pharmacologic action of the drug and are dose-dependent; others occur sporadically and relatively independent of dose. The latter (“idiosyncratic”) reactions are unpredictable and, in general, have no known underlying genetic basis. Many are antibody-mediated, as would be expected since cellular immune effector cells have little direct access to circulating blood cells. In this chapter, we will discuss idiosyncratic drug reactions affecting blood and blood forming tissues with an emphasis on those thought to be immune-mediated.


Drug sensitivity Drug-induced cytrpennia 



Adverse drug reaction


Autoimmune thrombocytopenic purpura


Drug-dependent antibody


Drug-induced immune hemolytic anemia


Drug-induced immune thrombocytopenia


Granulocyte colony simulating factor


Heparin-induced thrombocytopenia


Hemolytic uremic sundrome


Non-steroidal anti-inflammatory drug


Arginine-glycine-aspartic acid


  1. Adachi JD, Bensen WG, Kassam Y et al (1987) Gold induced thrombocytopenia: 12 cases and a review of the literature. Semin Arthritis Rheum 16:287–293PubMedCrossRefGoogle Scholar
  2. Andersohn F, Konzen C, Garbe E (2007) Non-chemotherapy drug-induced agranulocytosis: a systematic review of case reports. Ann Intern Med 146:657–665PubMedGoogle Scholar
  3. Andrès E, Maloisel F (2008) Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr Opin Hematol 15:15–21PubMedCrossRefGoogle Scholar
  4. Andrès E, Maloisel F, Kurtz JE, Kaltenbach G, Alt M, Weber JC et al (2002) Modern management of non-chemotherapy drug-induced agranulocytosis: a monocentric cohort study of 90 cases and review of the literature. Eur J Intern Med 13:324–328PubMedCrossRefGoogle Scholar
  5. Andrès E, Zimmer J, Affenberger S, Federici L, Alt M, Maloisel F (2006) Idiosyncratic drug-induced agranulocytosis: update of an old disorder. Eur J Intern Med 17:529–535PubMedCrossRefGoogle Scholar
  6. Arndt PA, Garratty G (2005) The changing spectrum of drug-induced immune hemolytic anemia. Semin Hematol 42:137–144PubMedCrossRefGoogle Scholar
  7. Artoni A, Li J, Mitchell B (2004) et al (2004) Integrin beta3 regions controlling binding of murine mAb 7E3: implications for the mechanism of integrin alphaIIbbeta3 activation. Proc Natl Acad Sci U S A 101:13114–13120PubMedCrossRefGoogle Scholar
  8. Aster RH (2000) Can drugs cause autoimmune thrombocytopenic purpura? Semin Hematol 37:229–238PubMedCrossRefGoogle Scholar
  9. Aster RH, Bougie DW (2007) Drug-induced immune thrombocytopenia. N Engl J Med 357:580–587PubMedCrossRefGoogle Scholar
  10. Bhatt V, Saleem A (2004) Review: drug-induced neutropenia–pathophysiology, clinical features, and management. Ann Clin Lab Sci 34:131–137PubMedGoogle Scholar
  11. Bougie D, Aster R (2001) Immune thrombocytopenia resulting from sensitivity to metabolites of naproxen and acetaminophen. Blood 97:3846–3850PubMedCrossRefGoogle Scholar
  12. Bougie D, Johnson ST, Weitekamp LA, Aster RH (1997) Sensitivity to a metabolite of diclofenac as a cause of acute immune hemolytic anemia. Blood 90:407–413PubMedGoogle Scholar
  13. Bougie DW, Wilker PR, Wuitschick ED, Curtis BR, Malik M, Levine S, Lind RN, Pereira J, Aster RH (2002) Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 100:2071–2076PubMedGoogle Scholar
  14. Bougie DW, Wilker PR, Aster RH (2006) Patients with quinine-induced immune thrombocytopenia have both “drug-dependent” and “drug-specific” antibodies. Blood 108:922–927PubMedCrossRefGoogle Scholar
  15. Bougie DW, Benito AI, Sanchez-Abarca LI, Torres R, Birenbaum J, Aster RH (2007) Acute thrombocytopenia caused by sensitivity to the glucuronide conjugate of acetaminophen. Blood 109:3608–3609PubMedCrossRefGoogle Scholar
  16. Christie DJ, Aster RH (1982) Drug-antibody-platelet interaction in quinine- and quinidine-induced thrombocytopenia. J Clin Invest 70:989–998PubMedCrossRefGoogle Scholar
  17. Christie DJ, Mullen PC, Aster RH (1985) Fab-mediated binding of drug-dependent antibodies to platelets in quinidine- and quinine-induced thrombocytopenia. J Clin Invest 75:310–314PubMedCrossRefGoogle Scholar
  18. Cunha PD, Lord RS, Johnson ST, Wilker PR, Aster RH, Bougie DW (2000) Immune hemolytic anemia caused by sensitivity to a metabolite of etodolac, a nonsteroidal anti-inflammatory drug. Transfusion 40:663–668PubMedCrossRefGoogle Scholar
  19. Curtis BR, Swyers J, Divgi A, McFarland JG, Aster RH (2002) Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 99:2054–2059PubMedCrossRefGoogle Scholar
  20. Curtis BR, Divgi A, Garritty M, Aster RH (2004) Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug. J Thromb Haemost 2:985–992PubMedCrossRefGoogle Scholar
  21. Curtis BR, Kaliszewski J, Marques MB, Saif MW, Nabelle L, Blank J, McFarland JG, Aster RH (2006) Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am J Hematol 81:193–198PubMedCrossRefGoogle Scholar
  22. Davoren A, Aster RH (2006) Heparin-induced thrombocytopenia and thrombosis. Am J Hematol 81:36–44PubMedCrossRefGoogle Scholar
  23. Dlott JS, Danielson CF, Blue-Hnidy DE, McCarthy LJ (2004) Drug-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a concise review. Ther Apher Dial 8:102–111PubMedCrossRefGoogle Scholar
  24. Fibbe WE, Claas FH, Van der Star-Dijkstra W, Schaafsma MR, Meyboom RH, Falkenburg JH (1986) Agranulocytosis induced by propylthiouracil: evidence of a drug dependent antibody reacting with granulocytes, monocytes and haematopoietic progenitor cells. Br J Haematol 64:363–373PubMedCrossRefGoogle Scholar
  25. Garratty G (1993) Immune cytopenia associated with antibiotics. Transfus Med Rev 7:255–267PubMedCrossRefGoogle Scholar
  26. Garratty G, Arndt PA (2007) An update on drug-induced immune hemolytic anemia. Immunohematology 23:105–119PubMedGoogle Scholar
  27. Garratty G, Arndt P, Prince HE, Shulman IA (1993) The effect of methyldopa and procainamide on suppressor cell activity in relation to red cell autoantibody production. Br J Haematol 84:310–315PubMedCrossRefGoogle Scholar
  28. Gottschall JL, Elliot W, Lianos E, McFarland JG, Wolfmeyer K, Aster RH (1991) Quinine-induced immune thrombocytopenia associated with hemolytic uremic syndrome: a new clinical entity. Blood 77:306–310PubMedGoogle Scholar
  29. Green FA, Jung CY, Rampal A, Lorusso DJ (1980) Alpha-methyldopa and the erythrocyte membrane. Clin Exp Immunol 40:554–560PubMedGoogle Scholar
  30. Guest I, Uetrecht J (1991) Drugs that induce neutropenia/agranulocytosis may target specific components of the stromal cell extracellular matrix. Med Hypotheses 53:145–151CrossRefGoogle Scholar
  31. Ibáñez L, Sabaté M, Ballarín E, Puig R, Vidal X, Laporte JR (2008) Agranulocytosis and Aplastic Anaemia Study Group of Barcelona. Use of granulocyte colony-stimulating factor (G-CSF) and outcome in patients with non-chemotherapy agranulocytosis. Pharmacoepidemiol Drug Saf 17:224–228PubMedCrossRefGoogle Scholar
  32. Johnson ST, Fueger JT, Gottschall JL (2007) One center’s experience: the serology and drugs associated with drug-induced immune hemolytic anemia–a new paradigm. Transfusion 47:697–702PubMedCrossRefGoogle Scholar
  33. Juang YC, Tsao TC, Chiang YC, Lin JL, Tsai YH (1992) Acute renal failure and severe thrombocytopenia induced by rifampicin: report of a case. J Formos Med Assoc 91:475–476PubMedGoogle Scholar
  34. Kaufman DW et al. (1996) Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur J Haematol 60(Suppl):55–59Google Scholar
  35. Kojouri K, Vesely SK, George JN (2001) Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes. Ann Intern Med 135:1047–1051PubMedGoogle Scholar
  36. Maloisel F, Andrès E, Kaltenbach G, Noel E, Martin-Hunyadi C, Dufour P (2004) Prognostic factors of hematological recovery in life-threatening nonchemotherapy drug-induced agranulocytosis. A study of 91 patients from a single center. Presse Med 33:1164–1168PubMedCrossRefGoogle Scholar
  37. Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE (1998) Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 97:1680–1688PubMedGoogle Scholar
  38. McMinn JR Jr, Cohen S, Moore J, Lilly S, Parkhurst J, Tarantino MD, Terrell DR, George JN (2003) Complete recovery from refractory immune thrombocytopenic purpura in three patients treated with etanercept. Am J Hematol 73:135–140PubMedCrossRefGoogle Scholar
  39. Montané E, Ibáñez L, Vidal X, Ballarín E, Puig R, García N, Laporte JR (2008) Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica 93:518–523PubMedCrossRefGoogle Scholar
  40. Otrock ZK, Mahfouz RA, Oghlakian GO, Salem ZM, Bazarbachi A (2005) Rituximab-induced acute thrombocytopenia: a report of two cases. Haematologica 90(Suppl):ECR23Google Scholar
  41. Petz LD (1993) Drug-induced autoimmune hemolytic anemia. Transfus Med Rev 7:242–254PubMedCrossRefGoogle Scholar
  42. Reddy JC, Shuman MA, Aster RH (2004) Quinine/quinidine-induced thrombocytopenia: a great imitator. Arch Intern Med 164:218–220PubMedCrossRefGoogle Scholar
  43. Reid DM, Shulman NR (1988) Drug purpura due to surreptitious quinidine intake. Ann Intern Med 108:206–208PubMedGoogle Scholar
  44. Salama A, Mueller-Eckhardt C (1985) The role of metabolite-specific antibodies in nomifensine-dependent immune hemolytic anemia. N Engl J Med 313:469–474PubMedCrossRefGoogle Scholar
  45. Salama A, Mueller-Eckhardt C (1987) On the mechanisms of sensitization and attachment of antibodies to RBC in drug-induced immune hemolytic anemia. Blood 69:1006–1010PubMedGoogle Scholar
  46. Salama A, Göttsche B, Mueller-Eckhardt C (1991) Autoantibodies and drug- or metabolite-dependent antibodies in patients with diclofenac-induced immune haemolysis. Br J Haematol 77:546–549PubMedCrossRefGoogle Scholar
  47. Salamon DJ, Nusbacher J, Stroupe T, Wilson JH, Hanrahan JB (2004) Red cell and platelet-bound IgG penicillin antibodies in a patient with thrombocytopenia. Semin Thromb Hemost 30:273–283CrossRefGoogle Scholar
  48. Shulman NR (1964) A mechanism of cell destruction in individuals sensitized to foreign antigens and its implications in autoimmunity. Ann Int Med 60:506–521PubMedGoogle Scholar
  49. Shulman NR, Reid DM (1993) Mechanisms of drug-induced immunologically mediated cytopenias. Transfus Med Rev 7:215–229PubMedCrossRefGoogle Scholar
  50. Smith ME, Reid DM, Jones CE, Jordan JV, Kautz CA, Shulman NR (1987) Binding of quinine- and quinidine-dependent drug antibodies to platelets is mediated by the Fab domain of the immunoglobulin G and is not Fc dependent. J Clin Invest 79:912–917PubMedCrossRefGoogle Scholar
  51. Sosler SD, Behzad O, Garratty G, Lee CL, Postaway N, Khomo O (1984) Acute hemolytic anemia associated with a chlorpropamide-induced apparent auto-anti-Jka. Transfusion 24:206–209PubMedCrossRefGoogle Scholar
  52. Stroncek DF, Herr GP, Maguire RB, Eiber G, Clement LT (1994) Characterization of the neutrophil molecules identified by quinine-dependent antibodies from two patients. Transfusion 34:980–985PubMedCrossRefGoogle Scholar
  53. Vidal F, Fontova R, Richart C (2003) Severe neutropenia and thrombocytopenia associated with infliximab. Ann Intern Med 139:W–W63Google Scholar
  54. Visentin GP, Wolfmeyer K, Newman PJ, Aster RH (1990) Detection of drug-dependent, platelet-reactive antibodies by antigen-capture ELISA and flow cytometry. Transfusion 30:694–700PubMedCrossRefGoogle Scholar
  55. von dem Borne AE, Pegels JG, van der Stadt RJ, van der Plas-van Dalen CM, Helmerhorst FM (1986) Thrombocytopenia associated with gold therapy: a drug-induced autoimmune disease? Br J Haematol 63:509–516Google Scholar
  56. Warkentin TE (2004) An overview of the heparin-induced thrombocytopenia syndrome. SeminThromb Hemost 30:273-83Google Scholar
  57. Warkentin TE (2007) Heparin-induced thrombocytopenia. Hematol Oncol Clin N Am 21:589–607Google Scholar
  58. Warkentin TE, Kwon P (2005) Immune thrombocytopenia associated with efalizumab therapy for psoriasis. Ann Intern Med 143:761–763PubMedGoogle Scholar
  59. Williams DP, Pirmohamed M, Naisbitt DJ, Uetrecht JP, Park BK (2000) Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine. Mol Pharmacol 58:207–216PubMedGoogle Scholar
  60. Wolf B, Conradty M, Grohmann R, Ruther E, Witzgall H, Londong V (1989) A case of immune complex hemolytic anemia, thrombocytopenia, and acute renal failure associated with doxepin use. J Clin Psychiatry 50:99–100PubMedGoogle Scholar
  61. Young NS, Kaufman DW (2008) The epidemiology of acquired aplastic anemia. Haematologica 93:489–492PubMedCrossRefGoogle Scholar
  62. Young NS, Scheinberg P, Calado RT (2008) Aplastic anemia. Curr Opin Hematol 15:162–168PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  1. 1.Blood Research InstituteBlood Center of WisconsinMilwaukeeUSA

Personalised recommendations